
Resolution of Injection Site Reactions After Switching to Adalimumab Biosimilar
Physicians and researchers from Saga University Hospital in Japan described a case of a 15-year-old girl with ulcerative colitis (UC) who switched from the adalimumab reference product to the biosimilar LBAL (LG Chem) after the eighth adalimumab dose when …